Shi Jian, Wang Keshan, Xiong Zhiyong, Yuan Changfei, Wang Cheng, Cao Qi, Yu Huang, Meng Xiangui, Xie Kairu, Cheng Zhixian, Yang Hongmei, Chen Ke, Zhang Xiaoping
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Institute of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Oncol Lett. 2020 Nov;20(5):272. doi: 10.3892/ol.2020.12135. Epub 2020 Sep 21.
Substantial research attention has been directed at exploring the mechanisms and treatment of renal cell carcinoma (RCC). Indeed, the association between inflammation and tumor phenotypes has been at the center of cancer research. Concomitant with research on the inflammation response and inflammatory molecules involved in RCC, new breakthroughs have emerged. A large body of knowledge now shows that treatments targeting inflammation and immunity in RCC provide substantial clinical benefits. Adequate analysis and a better understanding of the mechanisms of inflammatory factors in the occurrence and progression of RCC are highly desirable. Currently, numerous RCC treatments targeted at inflammation and immunotherapy are available. The current review describes in detail the link between inflammation and RCC.
大量的研究关注都集中在探索肾细胞癌（RCC）的发病机制和治疗方法上。事实上，炎症与肿瘤表型之间的关联一直是癌症研究的核心。随着对RCC中炎症反应和炎症分子的研究，新的突破不断涌现。现在大量的知识表明，针对RCC炎症和免疫的治疗具有显著的临床益处。对RCC发生和发展过程中炎症因子机制进行充分分析并加深理解是非常必要的。目前，有许多针对炎症的RCC治疗方法和免疫疗法可供选择。本综述详细描述了炎症与RCC之间的联系。
